Livzon Pharmaceutical Group Inc (000513) - Net Assets

Latest as of September 2025: CN¥15.37 Billion CNY ≈ $2.25 Billion USD

Based on the latest financial reports, Livzon Pharmaceutical Group Inc (000513) has net assets worth CN¥15.37 Billion CNY (≈ $2.25 Billion USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥24.54 Billion ≈ $3.59 Billion USD) and total liabilities (CN¥9.17 Billion ≈ $1.34 Billion USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Livzon Pharmaceutical Group Inc (000513) liquid assets ratio to evaluate the company's liquid asset resilience ratio.

Key Net Assets Metrics

Metric Value
Current Net Assets CN¥15.37 Billion
% of Total Assets 62.63%
Annual Growth Rate 13.28%
5-Year Change 9.28%
10-Year Change 209.9%
Growth Volatility 21.12

Livzon Pharmaceutical Group Inc - Net Assets Trend (1992–2024)

This chart illustrates how Livzon Pharmaceutical Group Inc's net assets have evolved over time, based on quarterly financial data. Also explore Livzon Pharmaceutical Group Inc asset portfolio for the complete picture of this company's asset base.

Annual Net Assets for Livzon Pharmaceutical Group Inc (1992–2024)

The table below shows the annual net assets of Livzon Pharmaceutical Group Inc from 1992 to 2024. For live valuation and market cap data, see Livzon Pharmaceutical Group Inc (000513) market capitalisation.

Year Net Assets Change
2024-12-31 CN¥14.91 Billion
≈ $2.18 Billion		 +0.94%
2023-12-31 CN¥14.77 Billion
≈ $2.16 Billion		 -1.14%
2022-12-31 CN¥14.94 Billion
≈ $2.19 Billion		 +4.37%
2021-12-31 CN¥14.31 Billion
≈ $2.09 Billion		 +4.92%
2020-12-31 CN¥13.64 Billion
≈ $2.00 Billion		 +11.12%
2019-12-31 CN¥12.28 Billion
≈ $1.80 Billion		 +4.47%
2018-12-31 CN¥11.75 Billion
≈ $1.72 Billion		 +4.60%
2017-12-31 CN¥11.23 Billion
≈ $1.64 Billion		 +58.09%
2016-12-31 CN¥7.11 Billion
≈ $1.04 Billion		 +47.73%
2015-12-31 CN¥4.81 Billion
≈ $703.84 Million		 +17.82%
2014-12-31 CN¥4.08 Billion
≈ $597.39 Million		 +13.26%
2013-12-31 CN¥3.60 Billion
≈ $527.45 Million		 +13.35%
2012-12-31 CN¥3.18 Billion
≈ $465.35 Million		 +5.60%
2011-12-31 CN¥3.01 Billion
≈ $440.69 Million		 +14.11%
2010-12-31 CN¥2.64 Billion
≈ $386.19 Million		 +18.59%
2009-12-31 CN¥2.23 Billion
≈ $325.65 Million		 +21.31%
2008-12-31 CN¥1.83 Billion
≈ $268.45 Million		 -7.86%
2007-12-31 CN¥1.99 Billion
≈ $291.33 Million		 +44.42%
2006-12-31 CN¥1.38 Billion
≈ $201.72 Million		 +11.31%
2005-12-31 CN¥1.24 Billion
≈ $181.22 Million		 +5.68%
2004-12-31 CN¥1.17 Billion
≈ $171.49 Million		 -0.22%
2003-12-31 CN¥1.17 Billion
≈ $171.87 Million		 +4.00%
2002-12-31 CN¥1.13 Billion
≈ $165.26 Million		 +8.93%
2001-12-31 CN¥1.04 Billion
≈ $151.72 Million		 +2.96%
2000-12-31 CN¥1.01 Billion
≈ $147.36 Million		 +3.40%
1999-12-31 CN¥973.90 Million
≈ $142.51 Million		 -8.68%
1998-12-31 CN¥1.07 Billion
≈ $156.05 Million		 +2.87%
1997-12-31 CN¥1.04 Billion
≈ $151.70 Million		 +34.70%
1996-12-31 CN¥769.62 Million
≈ $112.62 Million		 +16.20%
1995-12-31 CN¥662.32 Million
≈ $96.92 Million		 +6.23%
1994-12-31 CN¥623.47 Million
≈ $91.23 Million		 +14.05%
1993-12-31 CN¥546.67 Million
≈ $80.00 Million		 +98.39%
1992-12-31 CN¥275.56 Million
≈ $40.32 Million		 --

Equity Component Analysis

This analysis shows how different components contribute to Livzon Pharmaceutical Group Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have grown by 19753.4% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2024)

Component Amount Percentage
Retained Earnings CN¥11.76 Billion 84.84%
Common Stock CN¥911.35 Million 6.57%
Other Comprehensive Income CN¥1.13 Billion 8.14%
Other Components CN¥61.24 Million 0.44%
Total Equity CN¥13.86 Billion 100.00%

Livzon Pharmaceutical Group Inc Competitors by Market Cap

The table below lists competitors of Livzon Pharmaceutical Group Inc ranked by their market capitalization.

Company Market Cap
Viscofan
MC:VIS
 $2.81 Billion
Lotus Health Group Co
SHG:600186
 $2.81 Billion
Genting Malaysia Bhd
KLSE:4715
 $2.82 Billion
Tidewater Inc
NYSE:TDW
 $2.82 Billion
Shanghai Yuyuan Tourist Mart Co Ltd
SHG:600655
 $2.81 Billion
Axcelis Technologies Inc
NASDAQ:ACLS
 $2.81 Billion
Vista Energy S.A.B. de C.V.
BA:VIST
 $2.81 Billion
Shenzhen China Micro Semicon Co. Ltd. A
SHG:688380
 $2.81 Billion

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Livzon Pharmaceutical Group Inc's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2023 to 2024, total equity changed from 14,042,495,302 to 13,862,334,189, a change of -180,161,113 (-1.3%).
  • Net income of 2,061,095,805 contributed positively to equity growth.
  • Dividend payments of 1,340,306,595 reduced retained earnings.
  • Share repurchases of 858,562,382 reduced equity.
  • Other comprehensive income decreased equity by 52,052,313.

Equity Change Factors (2023 to 2024)

Factor Impact Contribution
Net Income CN¥2.06 Billion +14.87%
Dividends Paid CN¥1.34 Billion -9.67%
Share Repurchases CN¥858.56 Million -6.19%
Other Comprehensive Income CN¥-52.05 Million -0.38%
Other Changes CN¥9.66 Million +0.07%
Total Change CN¥- -1.28%

Book Value vs Market Value Analysis

This analysis compares Livzon Pharmaceutical Group Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 2.17x
  • The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
  • The price-to-book ratio has decreased from 97.39x to 2.17x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
1992-12-31 CN¥0.34 CN¥32.65 x
1994-12-31 CN¥0.75 CN¥32.65 x
1995-12-31 CN¥0.80 CN¥32.65 x
1996-12-31 CN¥0.90 CN¥32.65 x
1997-12-31 CN¥1.14 CN¥32.65 x
1998-12-31 CN¥1.16 CN¥32.65 x
1999-12-31 CN¥1.03 CN¥32.65 x
2000-12-31 CN¥1.05 CN¥32.65 x
2001-12-31 CN¥1.05 CN¥32.65 x
2002-12-31 CN¥1.09 CN¥32.65 x
2003-12-31 CN¥1.19 CN¥32.65 x
2004-12-31 CN¥1.30 CN¥32.65 x
2005-12-31 CN¥1.38 CN¥32.65 x
2006-12-31 CN¥1.53 CN¥32.65 x
2007-12-31 CN¥2.22 CN¥32.65 x
2008-12-31 CN¥2.03 CN¥32.65 x
2009-12-31 CN¥2.52 CN¥32.65 x
2010-12-31 CN¥2.97 CN¥32.65 x
2011-12-31 CN¥3.38 CN¥32.65 x
2012-12-31 CN¥3.55 CN¥32.65 x
2013-12-31 CN¥3.96 CN¥32.65 x
2014-12-31 CN¥4.37 CN¥32.65 x
2015-12-31 CN¥5.08 CN¥32.65 x
2016-12-31 CN¥7.41 CN¥32.65 x
2017-12-31 CN¥11.60 CN¥32.65 x
2018-12-31 CN¥11.42 CN¥32.65 x
2019-12-31 CN¥11.95 CN¥32.65 x
2020-12-31 CN¥12.90 CN¥32.65 x
2021-12-31 CN¥13.92 CN¥32.65 x
2022-12-31 CN¥14.83 CN¥32.65 x
2023-12-31 CN¥15.09 CN¥32.65 x
2024-12-31 CN¥15.07 CN¥32.65 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Livzon Pharmaceutical Group Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): 14.87%
  • The company shows good efficiency in utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: 17.45%
  • • Asset Turnover: 0.48x
  • • Equity Multiplier: 1.76x
  • Recent ROE (14.87%) is above the historical average (12.67%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
1992 21.50% 8.47% 1.18x 2.16x CN¥31.69 Million
1994 16.35% 16.85% 0.69x 1.41x CN¥39.28 Million
1995 12.20% 11.74% 0.62x 1.69x CN¥14.44 Million
1996 11.03% 11.29% 0.55x 1.78x CN¥7.59 Million
1997 4.47% 5.41% 0.54x 1.52x CN¥-54.95 Million
1998 4.01% 4.59% 0.57x 1.53x CN¥-61.03 Million
1999 0.18% 0.15% 0.73x 1.73x CN¥-88.55 Million
2000 1.13% 0.88% 0.74x 1.73x CN¥-81.22 Million
2001 5.48% 3.61% 0.83x 1.82x CN¥-41.51 Million
2002 6.52% 3.87% 0.86x 1.96x CN¥-33.00 Million
2003 8.83% 5.09% 0.85x 2.04x CN¥-12.26 Million
2004 10.89% 7.98% 0.71x 1.93x CN¥10.09 Million
2005 8.96% 6.63% 0.75x 1.80x CN¥-12.55 Million
2006 10.39% 8.75% 0.65x 1.84x CN¥5.20 Million
2007 26.17% 29.09% 0.59x 1.52x CN¥314.18 Million
2008 2.93% 2.53% 0.70x 1.64x CN¥-125.78 Million
2009 22.41% 18.55% 0.83x 1.45x CN¥266.67 Million
2010 16.61% 15.34% 0.74x 1.45x CN¥166.44 Million
2011 12.64% 11.36% 0.69x 1.62x CN¥75.05 Million
2012 14.68% 11.20% 0.70x 1.87x CN¥140.87 Million
2013 14.58% 10.56% 0.70x 1.96x CN¥153.04 Million
2014 13.96% 9.31% 0.76x 1.98x CN¥146.33 Million
2015 14.33% 9.40% 0.82x 1.86x CN¥188.02 Million
2016 12.06% 10.25% 0.73x 1.62x CN¥133.75 Million
2017 41.11% 51.91% 0.54x 1.48x CN¥3.35 Billion
2018 10.16% 12.21% 0.51x 1.64x CN¥16.98 Million
2019 11.67% 13.88% 0.52x 1.61x CN¥186.20 Million
2020 14.16% 16.30% 0.51x 1.70x CN¥504.19 Million
2021 13.66% 14.72% 0.54x 1.72x CN¥475.31 Million
2022 13.76% 15.12% 0.51x 1.79x CN¥521.81 Million
2023 13.91% 15.72% 0.50x 1.78x CN¥549.40 Million
2024 14.87% 17.45% 0.48x 1.76x CN¥674.86 Million

Industry Comparison

This section compares Livzon Pharmaceutical Group Inc's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

  • Industry: Drug Manufacturers - Specialty & Generic
  • Average net assets among peers: $1,939,477,649
  • Average return on equity (ROE) among peers: 1.73%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Livzon Pharmaceutical Group Inc (000513) CN¥15.37 Billion 21.50% 0.60x $2.81 Billion
Shenzhen Neptunus Bioengineering Co Ltd (000078) $1.06 Billion 5.59% 4.55x $1.22 Billion
Anhui Fengyuan Pharmaceutical Co Ltd (000153) $560.87 Million 4.60% 0.22x $438.59 Million
Shan Dong Dong-E E-Jiao Co Ltd (000423) $9.78 Billion 0.44% 0.12x $5.18 Billion
Wedge Industrial Co Ltd (000534) $1.10 Billion 8.67% 0.93x $2.95 Billion
Yunnan Baiyao Group Co Ltd (000538) $184.00 Million 12.94% 0.09x $13.85 Billion
Hainan Haiyao Co Ltd (000566) $294.63 Million -32.00% 2.31x $949.23 Million
Tus Pharmaceutical Group Co Ltd (000590) $583.33 Million 3.29% 0.50x $391.07 Million
Northeast Pharmaceutical Group Co Ltd (000597) $2.55 Billion 4.67% 3.16x $1.03 Billion
Jilin Aodong Pharmaceutical Group Co Ltd (000623) $1.35 Billion 7.34% 0.44x $3.30 Billion

About Livzon Pharmaceutical Group Inc

SHE:000513 China Drug Manufacturers - Specialty & Generic
Market Cap
$2.81 Billion
CN¥19.20 Billion CNY
Market Cap Rank
#5139 Global
#996 in China
Share Price
CN¥32.65
Change (1 day)
-0.55%
52-Week Range
CN¥32.54 - CN¥43.90
All Time High
CN¥1418.81
Categories
Companies in China Drug Manufacturers - Specialty & Generic
About

Livzon Pharmaceutical Group Inc. researches, develops, produces, exports, and sells pharmaceutical products, and active pharmaceutical ingredients (API) and intermediates in the People's Republic of China and internationally. The company offers leuprorelin acetate microspheres, urofollitropin, and menotropins for injection for the assisted reproduction field; Ilaprazole enteric-coated tablets, il… Read more